US FDA extends review of Humacyte's blood vessel implant-February 2024-www.financetom.com

US FDA extends review of Humacyte's blood vessel implant

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA extends review of Humacyte's blood vessel implant

Aug 9, 2024 1:46 PM

Aug 9 (Reuters) - Humacyte ( HUMA ) said on Friday the

U.S. Food and Drug Administration has extended its review of the

company's implant that can act as a replacement for an injured

or damaged blood vessel.

The health regulator needed additional time to complete its

review and did not disclose a new decision date, the company

said.

Previous page： Ahead of US midterm elections, Elon Musk recommends voting for Republicans Next page： UK finance minister Jeremy Hunt promises tax increases, spending cuts

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Ahead of US midterm elections, Elon Musk recommends voting for Republicans

Nov 7, 2022

"Shared power curbs the worst excesses of both parties, therefore I recommend voting for a Republican Congress, given that the Presidency is Democratic," Musk wrote in a tweet.

UK finance minister Jeremy Hunt promises tax increases, spending cuts

Nov 13, 2022

Ahead of Thursday’s Autumn Statement, when he will update Parliament on the government’s budget measures, Jeremy Hunt said he was forced to make “very difficult decisions” in his attempt to curb inflation and put the economy back on an even keel.

US State Department says visa processing expected to reach pre-pandemic levels in FY 2023

Nov 18, 2022

The US visa processing is rebounding faster than projected and is expected to reach prepandemic levels in Fiscal Year 2023, the State Department has said, addressing the growing concern over backlog of visa applications from countries like India.

Workers leave biggest iPhone plant to escape COVID-19 curbs

Oct 31, 2022

Tensions at the Zhengzhou iPhone plant underscore the economic and social costs of Xi Jinping’s Covid Zero policy, a rigorously policed system of mass testing and quarantine lockdowns that has fostered growing resentment.